Immutep Limited (IMMP)

Market Cap	42.65M -84.1%
Revenue (ttm)	5.28M +62.4%
Net Income	-55.97M
EPS	-0.04
Shares Out	1.47B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,016,406
Open	0.3400
Previous Close	0.3526
Day's Range	0.3190 - 0.3400
52-Week Range	0.3190 - 3.5300
Beta	1.64
Analysts	Hold
Price Target	5.50 (+1,612.33%)
Earnings Date	Apr 23, 2026

About IMMP

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase II...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1987
• Employees: 31
• Stock Exchange: NASDAQ
• Ticker Symbol: IMMP
• Website: https://www.immutep.com

Financial Performance

In fiscal year 2025, Immutep's revenue was 5.04 million, an increase of 31.28% compared to the previous year's 3.84 million. Losses were -61.43 million, 43.8% more than in 2024.

Financial numbers in AUD

Analyst Summary

According to 3 analysts, the average rating for IMMP stock is "Hold." The 12-month stock price target is $5.5, which is an increase of 1,612.33% from the latest price.

Price Target

$5.5

(1,612.33% upside)

Analyst Consensus: Hold